Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:

CARsgen Therapeutics to Raise $400 Million in Hong Kong IPO

publication date: Jun 9, 2021

Shanghai CARsgen Therapeutics is staging an IPO on the Hong Kong Exchange that could raise $400 million to support development of the company's CAR-T portfolio. The shares are scheduled to begin trading on June 18. Lilly Asia Ventures and New China Life are among nine cornerstone investors that will acquire $230 million of the shares. CARsgen is advancing 11 candidates for solid tumors and hematological malignancies including six clinical stage molecules. The company's lead drug is a BCMA CAR-T for multiple myeloma currently in a pivotal Phase II/III trial. More details....

Share this with colleagues:

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital